Mazdutide Single vial · Incretin / GLP-1
Strength
Volume pricing
Any mix of Express vials counts. Not combined with discount codes.
Add 1 more to unlock 5% off
Your basket is empty
With this one in, 1 vial more of anything and the whole basket is 5% off.
For laboratory research use only. Not for human or veterinary use.
Buying at volume? Mazdutide factory direct
About Mazdutide+
About Mazdutide
Mazdutide (development codes IBI362 and LY3305677) is a once-weekly dual GLP-1 and glucagon receptor agonist. Clinical programme status, as reported in the published record: a randomised, placebo-controlled multiple-ascending-dose phase 1b study in Chinese adults with overweight or obesity was published in EClinicalMedicine in 2021 (Ji et al.). A randomised, double-blind, placebo-controlled phase 2 trial was published in Nature Communications in 2023 (Ji et al.). The phase 3 GLORY-1 trial, "Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight", was published in the New England Journal of Medicine in 2025 (Ji et al., doi:10.1056/NEJMoa2411528). In June 2025 mazdutide received approval from China's National Medical Products Administration for chronic weight management. Mazdutide is not approved in the United Kingdom, the European Union or the United States. Peptx supplies mazdutide only as lyophilised reference material for laboratory research. It is not for human or animal consumption, and no therapeutic claim is made here. Trial outcome figures are reproduced on the Peptx research article for this compound as direct quotations with full attribution.
Mechanism
Mazdutide is a synthetic analogue based on the mammalian oxyntomodulin scaffold, engineered for once-weekly exposure. It binds and activates two class B G-protein-coupled receptors in parallel: the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). This distinguishes it from single-receptor GLP-1 agonists such as semaglutide and from the GLP-1/GIP co-agonist tirzepatide, which recruits the glucose-dependent insulinotropic polypeptide receptor instead of GCGR. Published pharmacology describes it as a "glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist" (Ji et al., Nature Communications, 2023). Receptor-level research interest centres on how parallel GLP-1R and GCGR signalling differs from GLP-1R-only or GLP-1R/GIPR signalling in in-vitro and preclinical systems.
Research on Mazdutide
Storage and handling
- Sealed and lyophilised, store at 2 to 8°C away from light and moisture. Minus 20°C for longer.
- Once reconstituted, keep refrigerated and avoid repeated freeze and thaw cycles.
- Bacteriostatic water is the usual diluent. The volume added sets the concentration in mg per mL.
- Vials carry a batch number for your laboratory records. Recent independent lab results are published in our COA Library.
FAQs
Can I order a single vial of Mazdutide without a minimum order?+
Yes. The single-vial range exists precisely so a laboratory can take one vial of Mazdutide rather than a full Factory Direct kit of 10. There is no minimum order quantity on this format.
How quickly does a Mazdutide single vial ship in the UK?+
Single vials are held in our UK facility and dispatched within 24 hours of a cleared payment on working days, on a tracked UK service. Orders placed at the weekend go out on the next working day.
How does the single vial differ from the factory-direct box?+
The compound and the manufacturing source are the same. The Factory Direct kit is a 10-vial pack and a lower per-vial cost, while the single vial is one vial from UK stock for small-scale or pilot work.
What purity is stated for Mazdutide?+
≥99% manufacturer-stated purity. Buyers are encouraged to run independent third-party verification, and our testing directory lists laboratories that perform it.
Is this Mazdutide vial for human use?+
No. Every Peptx product, including the single-vial range, is supplied strictly for laboratory research. It is not for human consumption, diagnosis, treatment or any clinical use.
What is mazdutide?+
Mazdutide (development codes IBI362 and LY3305677) is an oxyntomodulin-based dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics under licence from Eli Lilly. Peptx supplies it as laboratory reference material only.
What receptors does mazdutide act on?+
Two: the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Published pharmacology describes mazdutide as a glucagon-like peptide-1 and glucagon receptor dual agonist (Ji et al., Nature Communications, 2023).
What stage is the mazdutide clinical programme at?+
Phase 1b results were published in EClinicalMedicine in 2021, phase 2 results in Nature Communications in 2023, and the phase 3 GLORY-1 trial in the New England Journal of Medicine in 2025. Innovent announced Chinese NMPA approval for chronic weight management on 27 June 2025. Mazdutide is not approved in the UK, EU or US.
How does mazdutide differ from tirzepatide?+
Both are dual agonists, but at different receptor pairs: mazdutide acts at GLP-1R and the glucagon receptor, while tirzepatide acts at GLP-1R and the GIP receptor. See the mazdutide vs tirzepatide comparison for a receptor-level breakdown.
Is mazdutide supplied for human use?+
No. All material listed on this site is for laboratory, academic or institutional research only, and is not for human or animal consumption.
Other single vials in Incretin / GLP-1
Strictly for laboratory research. Not for human consumption, diagnosis or treatment.